Novartis Deal Reworked With $1.42B Milestone Potential as Q3 Revenue Tops Estimates
SDGR has more than doubled off its 52-week low of $10.945.
Summary
Schrodinger amended its Novartis collaboration, swapping out existing programs for two new ones and lifting potential milestone payments to $1.424 billion. That is the biggest piece of fresh information here, and it lands alongside Q3 revenue of $64.49 million, up 18.7% and above estimates, with hosted software revenue up 49%. Bristol Myers Squibb also adopted the Bunsen platform, a second validation of the software franchise. The adjusted loss was $0.50 per share. Analysts nudged their average 12-month target to $27.29 from $25.86, which still sits about 4% below the $29.50 stock price, so the sell side is not chasing the move. Watch the ASH meeting Dec. 12-15, where updated Phase 1 data for SGR-1505 gets an oral session.
At the time of this announcement, SDGR was trading at $29.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $10.95 to $33.78. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.